Sign in
ORKA Stock Price, Chart, Stats & News
Oruka Therapeutics, Inc.
Save
ORKA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -21.58% |
ROE | -25.30% |
D/E | 0.00x |
Interest coverage ratio | – |
ORKA valuation
P/E | – |
P/S | – |
P/B | 5.13x |
P/CF | -27.44x |
P/FCF | -18.84x |
P/OCF | -27.44x |
PEG | -0.76x |
EV multiple | -15.52x |
About
Oruka Therapeutics, Inc. functions as a biotechnology firm primarily dedicated to creating groundbreaking monoclonal antibody therapies. These treatments are designed to address Psoriasis (PsO) along with various other inflammatory and immunological (I&I) conditions. Its current development portfolio includes ORKA-001 and ORKA-002.
Similar securities
Based on sector and market capitalization
Report issue